TerminatedNCT03953118
Azithromycin for Meibomian Gland Disease
Medication studyAges 18+United StatesAnxiety
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- San FranciscoSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 1, 2019
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 2
- Sponsor
- University of California, San Francisco
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT03953118
- Official title
Show the full official title
A Randomized, Controlled Trial to Evaluate the Role of Oral Azithromycin in the Treatment of Symptomatic Meibomian Gland Disease and Its Effect on the Ocular Surface Microbiome
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
San Francisco
Questions about this study
Who is behind this study?
The study sponsor is University of California, San Francisco, a university.
Does this study involve medication?
Yes. The study involves medication, including Azithromycin Oral Product and Placebo Oral.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as terminated.
